Why is "Acorda Therapeutics" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-21 09:28:14
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
The Final Chapter: Acorda Therapeutics' Liquidation Proceeds - AD HOC NEWS
-
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
-
Acorda Therapeutics Announces Delisting from Nasdaq - Business Wire
-
Acorda Therapeutics, Inc. Announces Data Breach Following Compromised Emails - JD Supra
-
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China - prnewswire.com
-
Acorda Therapeutics announces departure of business operations chief - Drug Delivery Business
-
UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales - Fierce Pharma
-
Acorda files for bankruptcy, reveals asset sale plan - BioPharma Dive
-
Acorda dumps $363M Parkinson’s drug after patient deaths - Fierce Biotech
-
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S. - investors.biogen.com
-
John Varian Joins Acorda Therapeutics Board of Directors - citybiz
-
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement - Business Wire
-
Batycky exits Acorda to head up new biotech - Fierce Biotech
-
Why Acorda Therapeutics Shares Gaining Today? - Yahoo Finance
-
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda - Fierce Pharma
-
Acorda Therapeutics Chief Operating Officer Lauren Sabella to Retire - citybiz
-
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent - Business Wire
-
Acorda Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference - Fierce Biotech
-
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics - Business Wire
-
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 - Business Wire
-
After $185M asset buy, Merz Therapeutics plots US workforce expansion as CEO eyes more deals - Fierce Pharma
-
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz - BioSpace
-
Parkinson’s Therapy CVT-301 Doesn’t Alter Lung Function, Acorda Therapeutics Reports - Parkinson's News Today
-
Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Mark - GuruFocus
-
Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today - Fox Business
-
Ahead of bankruptcy sale, Acorda fights on with new Inbrija TV spot - Fierce Pharma
-
Acorda Therapeutics Stock Price Forecast. Should You Buy ACOR? - StockInvest.us
-
In $185M deal, Merz purchases Parkinson’s, MS therapeutics from Acorda - Healio
-
Acorda loses Nasdaq listing to cap biotech’s end - Pharmaceutical Technology
-
FRAUD AND MANIPULATION—S.D.N.Y.:... - VitalLaw.com
-
At a Glance: July 18 - Crain's New York Business
-
Acorda Therapeutics (ACOR) Stock Price, News & Analysis - MarketBeat
-
Lake DeForest Reservoir Designated State Landmark By NY Chapter Of American Water Works Association; Acorda Therapeutics In Pearl River Files Chapter 11 Bankruptcy, Lays Off Entire Staff; Briefs - rcbizjournal.com
-
Acorda Therapeutics Breaks Resistance, Hits New High - RTTNews
-
Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers - MedCity News
-
Fighting talk: Acorda gets combative in new Inbrija Parkinson's campaign after lackluster launch - Fierce Pharma
-
Acorda launches new campaign, website for Inbrija for Parkinson's... - Parkinson's News Today
-
Salary Series: Acorda Therapeutics, Biospecifics Technologies and Bristol-Myers Squibb - Crain's New York Business
-
Acorda wins big over thwarted patent challenger Bass as PTO upholds Ampyra's IP - Fierce Pharma
-
Acorda Therapeutics : ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder) - marketscreener.com
-
Sunovion focuses on Kynmobi's easy dosing as it launches into crowded Parkinson's market - Fierce Pharma
-
Accorda Acquires Biotie Therapies for $363 Million - Genetic Engineering and Biotechnology News
-
Elvis Ruiz, 29 - Westchester Magazine
-
Biotech Acorda buys Finnish firm Biotie & its Parkinson’s candidates for $363M - BioPharma Dive
-
Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com
-
Trial miss derails Acorda’s Ampyra plans - BioPharma Dive
-
Sun Pharma Settles Patent Litigation with Acorda Therapeutics - NDTV Profit
-
Federal court rules Ampyra patents invalid, sinking Acorda stock - BioPharma Dive
-
High school science fair draws best and brightest - The Journal News | lohud.com
-
Acorda Therapeutics shares rise after IPO - Crain's New York Business
-
Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today - Wisconsin State Journal
-
Acorda Therapeutics gets $11.5 million - Crain's New York Business
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.